Vvital Biomed
Transcatheter Mitral Valve Repair Technology
Health Tech & Life Sciences
Non Active, Feb 2022 ceased to operate
Company Overview
Snapshot
Founded in December 2016 by Nir Golan and Aram K.Smolinsky, Vvital Biomed operates with 1–10 employees. The company secured funding in one round from The Trendlines Group. Vvital Biomed joined Trendlines in December 2018.
Business overview
Vvital Biomed is a Health Tech & Life Sciences company focused on developing advanced medical devices. The company's core technology involves transcatheter mitral valve repair (TMVR), aiming to provide a stable solution that is less affected by systolic pressure load or annular dilatation. Vvital Biomed serves the medical treatment and therapeutics market, specifically within cardiology, targeting doctors and healthcare providers globally.
Log in to access full profile ›Company Intelligence Q&A
- What is Vvital Biomed's primary focus?
- Vvital Biomed is developing technology for transcatheter mitral valve repair (TMVR), aiming to create a stable device that simplifies the TMVR procedure and is less affected by physiological pressures.
- When was Vvital Biomed founded?
- Vvital Biomed was founded in December 2016.
- Who are the founders of Vvital Biomed?
- Nir Golan serves as Co-founder & CEO, and Aram K.Smolinsky serves as Co-founder & CMO of Vvital Biomed.
- When did Vvital Biomed join Trendlines?
- Vvital Biomed joined Trendlines in December 2018.
- What is the current status of Vvital Biomed?
- Vvital Biomed ceased to operate in February 2022.